Abstract
This work is to analyze pooled clinical data using different radiobiological models and to understand the relationship between biologically effective dose (BED) and tumor control probability (TCP) for stereotactic body radiotherapy (SBRT) of early-stage non-small cell lung cancer (NSCLC). The clinical data of 1-, 2-, 3-, and 5-year actuarial or Kaplan–Meier TCP from 46 selected studies were collected for SBRT of NSCLC in the literature. The TCP data were separated for Stage T1 and T2 tumors if possible, otherwise collected for combined stages. BED was calculated at isocenters using six radiobiological models. For each model, the independent model parameters were determined from a fit to the TCP data using the least chi-square (χ2) method with either one set of parameters regardless of tumor stages or two sets for T1 and T2 tumors separately. The fits to the clinic data yield consistent results of large α/β ratios of about 20 Gy for all models investigated. The regrowth model that accounts for the tumor repopulation and heterogeneity leads to a better fit to the data, compared to other 5 models where the fits were indistinguishable between the models. The models based on the fitting parameters predict that the T2 tumors require about additional 1 Gy physical dose at isocenters per fraction (⩽5 fractions) to achieve the optimal TCP when compared to the T1 tumors. In conclusion, this systematic analysis of a large set of published clinical data using different radiobiological models shows that local TCP for SBRT of early-stage NSCLC has strong dependence on BED with large α/β ratios of about 20 Gy. The six models predict that a BED (calculated with α/β of 20) of 90 Gy is sufficient to achieve TCP ⩾ 95%. Among the models considered, the regrowth model leads to a better fit to the clinical data.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 286-294 |
| Number of pages | 9 |
| Journal | Radiotherapy and Oncology |
| Volume | 122 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1 2017 |
Fingerprint
Keywords
- Early stage non-small cell lung cancer
- Stereotactic body radiation therapy
- Tumor control probability modeling
ASJC Scopus subject areas
- Hematology
- Oncology
- Radiology Nuclear Medicine and imaging
Cite this
Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models. / Liu, Feng; Tai, An; Lee, Percy; Biswas, Tithi; Ding, George X.; El Naqa, Isaam; Grimm, Jimm; Jackson, Andrew; Kong, Feng Ming; LaCouture, Tamara; Loo, Billy; Miften, Moyed; Solberg, Timothy; Li, X. Allen.
In: Radiotherapy and Oncology, Vol. 122, No. 2, 01.02.2017, p. 286-294.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models
AU - Liu, Feng
AU - Tai, An
AU - Lee, Percy
AU - Biswas, Tithi
AU - Ding, George X.
AU - El Naqa, Isaam
AU - Grimm, Jimm
AU - Jackson, Andrew
AU - Kong, Feng Ming
AU - LaCouture, Tamara
AU - Loo, Billy
AU - Miften, Moyed
AU - Solberg, Timothy
AU - Li, X. Allen
PY - 2017/2/1
Y1 - 2017/2/1
N2 - This work is to analyze pooled clinical data using different radiobiological models and to understand the relationship between biologically effective dose (BED) and tumor control probability (TCP) for stereotactic body radiotherapy (SBRT) of early-stage non-small cell lung cancer (NSCLC). The clinical data of 1-, 2-, 3-, and 5-year actuarial or Kaplan–Meier TCP from 46 selected studies were collected for SBRT of NSCLC in the literature. The TCP data were separated for Stage T1 and T2 tumors if possible, otherwise collected for combined stages. BED was calculated at isocenters using six radiobiological models. For each model, the independent model parameters were determined from a fit to the TCP data using the least chi-square (χ2) method with either one set of parameters regardless of tumor stages or two sets for T1 and T2 tumors separately. The fits to the clinic data yield consistent results of large α/β ratios of about 20 Gy for all models investigated. The regrowth model that accounts for the tumor repopulation and heterogeneity leads to a better fit to the data, compared to other 5 models where the fits were indistinguishable between the models. The models based on the fitting parameters predict that the T2 tumors require about additional 1 Gy physical dose at isocenters per fraction (⩽5 fractions) to achieve the optimal TCP when compared to the T1 tumors. In conclusion, this systematic analysis of a large set of published clinical data using different radiobiological models shows that local TCP for SBRT of early-stage NSCLC has strong dependence on BED with large α/β ratios of about 20 Gy. The six models predict that a BED (calculated with α/β of 20) of 90 Gy is sufficient to achieve TCP ⩾ 95%. Among the models considered, the regrowth model leads to a better fit to the clinical data.
AB - This work is to analyze pooled clinical data using different radiobiological models and to understand the relationship between biologically effective dose (BED) and tumor control probability (TCP) for stereotactic body radiotherapy (SBRT) of early-stage non-small cell lung cancer (NSCLC). The clinical data of 1-, 2-, 3-, and 5-year actuarial or Kaplan–Meier TCP from 46 selected studies were collected for SBRT of NSCLC in the literature. The TCP data were separated for Stage T1 and T2 tumors if possible, otherwise collected for combined stages. BED was calculated at isocenters using six radiobiological models. For each model, the independent model parameters were determined from a fit to the TCP data using the least chi-square (χ2) method with either one set of parameters regardless of tumor stages or two sets for T1 and T2 tumors separately. The fits to the clinic data yield consistent results of large α/β ratios of about 20 Gy for all models investigated. The regrowth model that accounts for the tumor repopulation and heterogeneity leads to a better fit to the data, compared to other 5 models where the fits were indistinguishable between the models. The models based on the fitting parameters predict that the T2 tumors require about additional 1 Gy physical dose at isocenters per fraction (⩽5 fractions) to achieve the optimal TCP when compared to the T1 tumors. In conclusion, this systematic analysis of a large set of published clinical data using different radiobiological models shows that local TCP for SBRT of early-stage NSCLC has strong dependence on BED with large α/β ratios of about 20 Gy. The six models predict that a BED (calculated with α/β of 20) of 90 Gy is sufficient to achieve TCP ⩾ 95%. Among the models considered, the regrowth model leads to a better fit to the clinical data.
KW - Early stage non-small cell lung cancer
KW - Stereotactic body radiation therapy
KW - Tumor control probability modeling
UR - http://www.scopus.com/inward/record.url?scp=85006942616&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006942616&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2016.11.006
DO - 10.1016/j.radonc.2016.11.006
M3 - Review article
C2 - 27871671
AN - SCOPUS:85006942616
VL - 122
SP - 286
EP - 294
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
SN - 0167-8140
IS - 2
ER -